Brief: Orexo Strengthens IP Rights For Overdose Rescue Drug OX124

Orexo AB

27/01/2021 07:12

Jan 27 (Reuters) - Orexo AB  ORX.ST :
    * OREXO STRENGTHENS IP RIGHTS FOR OVERDOSE RESCUE DRUG OX124
    * PATENT PROTECTION UNTIL 2039
    * NEW PATENT, US 10,898,480, IS SECOND US PATENT FOR OX124
    * OX124 IS PLANNED TO ENTER A PIVOTAL BRIDGING STUDY IN Q2
2021
    * A NEW DRUG APPLICATION (NDA) IS EXPECTED TO BE FILED WITH
US
FOOD AND DRUG ADMINISTRATION (FDA) IN Q1 2022
    * OX124 BEING GRANTED FAST TRACK DESIGNATION BY FDA, WHICH
IS
EXPECTED TO BE RECEIVED IN Q1 2021
    * POTENTIAL NET SALES FOR OX124, FIVE YEARS POST LAUNCH, IS
IN
RANGE OF USD 70 - 110 MILLION.

Source text for Eikon:  ID:nWkr6GprMR 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))